Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 12,934

Document Document Title
WO/2018/132751A1
A cancer targeting composition, kit, and method for treatment of cancer cells overexpressing somatostatin receptors is disclosed. The composition includes a radioisotope, a chelator, and a targeting moiety. The chelator includes a nitrog...  
WO/2018/131911A1
The present invention provides a radioactive compound for contrasting malignant melanoma and use as a contrast medium using the same for PET contrast.  
WO/2018/129284A1
The presently disclosed subject matter provides compositions and methods comprising isolated antibodies that can recognize human prostate-specific membrane antigen (PSMA). The presently disclosed antibodies can be used to for imaging and...  
WO/2018/126280A1
The present invention provides a method of preventing damage to non-neoplastic cells i.e. healthy cells by irradiating with a low-dose radiation to the non-neoplastic cells, wherein the low-dose radiation is used to initiate a protective...  
WO/2018/126183A2
Provided herein are compositions useful for imaging HER3. An exemplary composition provided herein is useful as a radiotracer for position emission tomography (PET) imaging. Methods of imaging HER3 and combination therapies comprising th...  
WO/2018/116274A1
The invention is directed to a body comprising oxides of lanthanides, in particular holmium oxide (Ho2O3), which are supported on a sulphur containing carbon based particle and to a process for producing said body.  
WO/2018/115204A1
A peptide ligand specific for MT1 -MMP comprising a polypeptide comprising two diaminopropionic acid (Dap) or N-alkyldiaminopropionic acid (N-AlkDap) residues, and a third residue selected from cysteine, Dap or N-AlkDap, separated by at ...  
WO/2018/119313A1
The presently disclosed subject matter provides compositions, kits, and methods comprising imaging agents that can detect Programmed Death Ligand 1 (PD-L1). The presently disclosed imaging agents can be used to detect diseases and disord...  
WO/2018/117847A1
The invention is directed to the use of a body comprising oxides of lanthanides, in particular holmiun oxide (H02O3), which are supported on a sulphur containing carbon based particle in therapeutic applications.  
WO/2018/115299A1
The present invention relates to the use of radiopharmaceuticalshaving a radioactive half-life of less than 21 minutes,such as oxygen-15 labeled water (H2 15O) in blood flow imaging using PET (Positron emission tomography) scanning techn...  
WO/2018/115148A1
The present application provides a means for differential diagnosis of Parkinson's disease and the clinically similar Parkinsonian disorders multiple system atrophy with predominantly Parkinsonian features (MSA-P) and progressive supranu...  
WO/2018/115203A1
A compound comprising at least one looped peptide structure attached via at least one alkylamino linkage to a scaffold. Preferably the looped peptide structure is a Bicycle structure comprising two peptide loops attached to the scaffold ...  
WO/2018/111099A1
The invention relates to biomarkers and diagnostic methods for determining the presence and/or risk of cerebral amyloid angiopathy (CAA) as well as to methods for screening for treatments for CAA.  
WO/2018/111989A1
The present teachings relate generally to conjugates and methods for imaging a tumor microenvironment in a patient, and to conjugates and methods for imaging cancer-associated fibroblasts (CAFs) in the tumor microenvironment of a patient...  
WO/2018/111978A1
FN3 domains that specifically bind to CD137, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and them are useful in therapeutic and diagnostic applications.  
WO/2018/108287A1
The invention relates to a method for treating PSMA expressing cancers, wherein the method comprises administering to patient in need thereof an effective amount of one or more Ac-225-radiopharmaceuticals, wherein the effective amount of...  
WO/2018/107205A1
The invention relates to a radiolabelled material comprising a polymer, a radioactive isotope, and an immobilizing agent, wherein the immobilizing agent is capable of immobilizing the radioactive isotope on or in the polymer, and wherein...  
WO/2018/107246A1
The present invention provides a particulate material, a therapeutic, a therapeutic device and a method of improving the treatment of cancer, in particular liver cancer in a patient in need thereof.  
WO/2018/111973A1
Fibronectin type III domains (FN3) that specifically bind to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, and detectably labeled FN3 domains...  
WO/2018/109164A1
The present invention relates to a labeling procedure for the incorporation, in mild reaction conditions, of sensitive and thermosensitive targeting molecules into a [99m Tc(N)(PNP)]-based compound suitable for a kit formulation.  
WO/2018/107082A1
The present invention provides methods for the identification of patients with an inflammatory or autoimmune disease that demonstrate an inadequate response to treatment with a multi-Fc therapeutic, and the determination of an optimal do...  
WO/2018/104900A1
Pharmaceutical formulation comprising 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine and at least one buffering agent in a aqueous vehicle, wherein the formulation has a pH value comprised between 4.0 and 5.5, preferably between 4.5 and 5....  
WO/2018/102372A1
Described herein are novel conjugates containing an inhibitor (e.g., a PSMA inhibitor, e.g., a gastrin-releasing peptide receptor inhibitor) and metal chelator that are covalently attached to a macromolecule (e.g., a nanoparticle, a poly...  
WO/2018/102682A1
Radiolabeled anti-PD-L1 antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of PD-L1 proteins in a patient or sample.  
WO/2018/102457A1
Disclosed herein is a method of screening AML patients who are unlikely to respond to or are not responsive to induction chemotherapy. The method includes detecting the expression level of FOXC1 in a sample obtained from the AML patient,...  
WO/2018/096075A1
The invention relates to a material for the 3-dimensional printing of scaffold structures on a 3D printer as well as to a medical implant (1) made of this type of material and the use of this type of material for manufacturing a medical ...  
WO/2018/097239A1
The present invention addresses the problem of providing a clearing agent which is capable of, after administering a fusant of a streptavidin mutant with a molecular probe, preventing the localization of the fusant at a target site such ...  
WO/2018/091058A1
There is provided a 177-Lu labelled peptide for site-specific targeting of TF thereby enabling treatment of a cancer disease associated with high TF expression; e.g. treatment of cancer by administering to a patient an effective amount o...  
WO/2018/091043A1
The invention relates to a method for producing a radiofluorinated compound which has an aromatic or heteroaromatic ring which carries [18F] fluorine as the first substituent, a bonding unit which can bond to a peptide or a peptide mimet...  
WO/2018/094005A1
Provided herein are compounds useful as imaging agents. Exemplary compounds provided herein are useful as myeloperoxidase imaging agents using positron emission tomography or fluorescence imaging techniques. Methods for preparing the com...  
WO/2018/087028A1
The present invention relates to cyclic peptide compounds which inhibit or antagonize the binding of methylglyoxal (MG) and/or other reactive carbonyl species (RCS) to an arginine-or lysine- containing protein. Preferred scavenger compou...  
WO/2018/089491A1
A method of manufacturing 2-(1-{6-[(2-[F-18]fluoroethyl)(methyl)amino]-2-naphthyl}ethy lidene)-malononitrile ([F-18]FDDNP) utilizes a semi-automated module that is used to perform fluorination, pre-purification, separation, product extra...  
WO/2018/089772A1
The presently disclosed subject matter relates to the administration of a KMT2D inhibitor for the treatment of a cancer. The present invention is based on the discovery that upon PI3K inhibition, KMT2D activity is upregulated, resulting ...  
WO/2018/089690A1
A system includes a control device and a magnetic device coupled to the control device. The magnetic device is configured to inductively couple to a treatment target including one or more cells exposed to an agent, and includes one or mo...  
WO/2018/089688A1
Compositions and methods for treating cancer that include administering a therapeutically effective amount of a tumor suppressor mRNA complexed with a delivery vehicle as described herein, e.g., a nanoparticle.  
WO/2018/084836A1
Anti-TMCC3 immunoconjugates are provided. The invention also provides methods of using the immunoconjugates in the treatment or detection of TMCC3-pocitive cancers.  
WO/2018/081860A1
The present invention relates to formulations of radiolabelled compounds that are of use in radiotherapy and diagnostic imaging.  
WO/2018/085769A1
The present invention provides a method for removing cysteine caps from antibodies and re-capping the antibodies with cysteine molecules. The methods include, inter alia, culturing a host cell comprising a protein molecule having at leas...  
WO/2018/079882A1
The present invention relates to a compound marked with a radioactive isotope used for positron emission tomography (PET) for imaging atherosclerotic arterial plaque, which is a cause of cardio-cerebrovascular diseases; and a production ...  
WO/2018/081447A1
The present invention relates to compositions and methods for reducing the risk and/or extent of radiocontrast-induced nephropathy ("RIN"') for kidney-imaging procedures that employ a radiocontrast medium. It is based, at least in part, ...  
WO/2018/070734A1
The present invention relates to a marking material having a contrasting effect and tissue adhesion characteristics and comprising core/shell nanoparticles, which are structured to comprise a core having a contrasting effect and a silica...  
WO/2018/069329A1
Provided is a process of producing activated particles comprising 188Re-isotopes and/or 186Re-isotopes by irradiating non-volatile and water-insoluble starting particles comprising a rhenium compound with neutrons. Further provided is a ...  
WO/2018/071911A1
This disclosure relates to nanoparticles comprising a surface molecule that binds or blocks PD-L1. In certain embodiments, the disclosure relates to methods of using peptides or nanoparticles disclosed herein for the treatment of cancer....  
WO/2018/067361A1
This disclosure relates to synthetic ligands for detecting PD-L1 in a sample or subject. The ligand can be labeled with a variety of detectable labels allowing of visualization and quantification. The ligand provides an alternative PD-L1...  
WO/2018/067991A1
Dysfunctional or exhausted T cells arise in chronic diseases including chronic viral infections and cancer, and express high levels of co-inhibitory receptors. Therapeutic blockade of these receptors has clinical efficacy in the treatmen...  
WO/2018/068060A1
Compositions and methods of using these compositions that can include a targeting moiety and a therapeutic agent are described herein. These compositions can be used for di-agnosing and/or treating flaviviridae-family viruses including Z...  
WO/2018/067751A1
The present invention is directed to compositions and methods related to carbohydrate-based backbone CD206-targeting molecules. Described herein are compositions for diagnosing and treating disorders, for example but without limitation, ...  
WO/2018/063638A1
Provided herein are a variety of metal chelators as well as methods of use thereof.  
WO/2018/057635A1
A shielding assembly may be used in a nuclear medicine infusion system that generates and infuse radioactive liquid into a patient undergoing a diagnostic imaging procedure. In some examples, the shielding assembly has multiple compartme...  
WO/2018/057915A1
Provided here are compositions comprising engineered lymphocytes that secrete bispecific engager molecules, thereby activating T cells in the local environment to kill target cells. In particular embodiments, engineered lymphocytes selec...  

Matches 1 - 50 out of 12,934